On page 872 of the original version of this article, under the subheading "New vaccine development technologies", there was an error in the sentence that began: “AS04 (GlaxoSmithKline), an adjuvant composed of aluminium salt and the Toll-like receptor (TLR) against MPL”. This sentence should begin: “AS04 (GlaxoSmithKline), an adjuvant composed of aluminium salt and the Toll-like receptor (TLR) agonist MPL”. The authors apologize for this error.